Where can I read DGX's latest 10-K?

DGX's latest annual report, a 10-K, was filed on Feb 26, 2026 for the fiscal year ended Dec 31, 2025. It is linked above and opens on EDGAR, the SEC's own site, where every exhibit is also listed.

When did DGX last file an 8-K?

On Oct 6, 2026 it covered directors or officers; compensation. An 8-K reports a material event between quarterly reports; the one that furnishes the quarter's results is filed under Item 2.02, last on Jul 23, 2026.

Are DGX insiders buying or selling?

Over the last 13 months insiders sold $24.7M in 18 sales and bought nothing on the open market; 92 other transactions (awards, exercises, tax withholding, gifts and plan purchases). The most recent sale: Davis J. E. (CEO and President · Director) sold 10,000 shares on Sep 1, 2026 for $2.4M, under a 10b5-1 plan. Every figure is as the insider filed it on Form 4; a sale under a 10b5-1 plan was scheduled in advance.

How many SEC filings has DGX made?

2,370 filings are on EDGAR under the registrant records that have been Quest Diagnostics Incorporated, going back to 1996; 1,504 of them are insider ownership forms (Forms 3, 4, 5 and 144).

DGX

$238.82+0.72%

as of close, Oct 21, 2026

☾ AH $238.82 +0.72%

Quest Diagnostics IncorporatedStock · HealthcareS&P 500 Equal Weight · 0.2% of RSPS&P 500 · 0.04% of SPYRussell 1000 · 0.03% of IWBUS Stock Market · 0.03% of VTIRussell 3000 · 0.03% of IWVMSCI ACWI · 0.03% of ACWIMSCI World · 0.02% of URTH

PeersTMOLHMTDRVTYAIDXX

Share this page

DGX SEC filings (2026)

CIK 1022079 · Services-Medical Laboratories (SIC 8071) · incorporated in DE · fiscal year ends in December

2,370 filings on EDGAR since 1996 · 32 annual, 89 quarterly, 305 current · financial statements · earnings

Latest 10-K

Feb 26, 2026

fiscal year to Dec 31, 2025

Latest 10-Q

Jul 23, 2026

quarter to Jun 30, 2026

Latest 8-K

Oct 6, 2026

Directors or officers; compensation

Last earnings release

Jul 23, 2026

$3.12 vs $2.81 · ▲ 8.6%

Filings on file

2,370

since 1996, 1,504 insider forms

What happened, last 12 months#

Every earnings release with its print, every report with its quarter, the other 8-Ks by the headline of the press release they furnish or by their items, the proxy statements, and each day an insider bought or sold — newest first, each line opening the filing on EDGAR. The index by form and year follows.

June 2026

May 2026

May 218-K8-K · Shareholder vote results
May 88-K8-K · Material definitive agreement
May 18-K8-K · Quest Diagnostics Prices $500 Million of Senior NotesOther events

April 2026

Apr 22ReportQuarterly report, Q1 2026 — revenue $2.90B (+9% y/y), net income $252.0M, EPS $2.24
Apr 21EarningsEarnings release — EPS $2.50 vs $2.37 est. (+5.5%); revenue $2.90B (+9% y/y) 4.4%
Apr 6ProxyProxy · Additional proxy materials
Apr 6ProxyProxy · Proxy statement

March 2026

Mar 128-K8-K · Quest Diagnostics Elects Timothy Wentworth, Former CEO of Walgreens Boots Alliance, Evernorth Health Services and Express Scripts, to Board of DirectorsDirectors or officers; compensation; Regulation FD disclosure
Mar 5Insider saleDoherty Catherine T. (EVP, Regional Businesses) sold 5,558 shares for $1.1M at $206.21 under a 10b5-1 plan
Mar 5Insider salePREVOZNIK MICHAEL E (SVP & General Counsel) sold 3,878 shares for $800K at $206.21 under a 10b5-1 plan
Mar 5Insider salePlewman Patrick (SVP for Diagnostic Services) sold 2,855 shares for $589K at $206.21 under a 10b5-1 plan
Mar 4Insider saleKUPPUSAMY KARTHIK (SVP, Clinical Solutions) sold 2,628 shares for $538K at $204.86
Mar 3Insider saleDoherty Catherine T. (EVP, Regional Businesses) sold 632 shares for $131K at $207.73 under a 10b5-1 plan
Mar 3Insider salePREVOZNIK MICHAEL E (SVP & General Counsel) sold 526 shares for $109K at $207.73 under a 10b5-1 plan
Mar 3Insider salePlewman Patrick (SVP for Diagnostic Services) sold 410 shares for $85K at $207.73 under a 10b5-1 plan
Mar 2Insider saleDavis J. E. (CEO and President · Director) sold 10,000 shares for $2.1M at $212.52 under a 10b5-1 plan

February 2026

Feb 26ReportAnnual report, FY2025 — revenue $11.04B (+12% y/y), net income $992.0M, EPS $8.75
Feb 19Insider saleDoherty Catherine T. (EVP, Regional Businesses) sold 1,433 shares for $294K at $204.83 under a 10b5-1 plan
Feb 19Insider salePREVOZNIK MICHAEL E (SVP & General Counsel) sold 1,111 shares for $228K at $204.83 under a 10b5-1 plan
Feb 19Insider salePlewman Patrick (SVP for Diagnostic Services) sold 958 shares for $196K at $204.83 under a 10b5-1 plan
Feb 13Insider saleDoherty Catherine T. (EVP, Regional Businesses) sold 26,165 shares for $5.4M at $205.21–$209.10 under a 10b5-1 plan
Feb 10EarningsEarnings release — EPS $2.42 vs $2.36 est. (+3.0%); revenue $2.81B (+7% y/y) 7.4%
Feb 10Insider salePlewman Patrick (SVP for Diagnostic Services) sold 5,662 shares for $1.2M at $204.00 under a 10b5-1 plan

January 2026

Jan 128-K8-K · Results of operations; Regulation FD disclosure

October 2025

Oct 21EarningsEarnings release — EPS $2.60 vs $2.51 est. (+3.6%); revenue $2.82B (+13% y/y) 3.0%
Oct 21ReportQuarterly report, Q3 2025 — revenue $2.82B (+13% y/y), net income $245.0M, EPS $2.16

Insider transactions#

What officers, directors and 10% holders reported on Forms 4 and 5 over the last 13 months, from the documents themselves: one insider’s trades of one kind on one day are one row, with the shares, the price range and the total as filed. Open-market buys and sells first; awards, exercises, tax withholding, gifts and employee-plan purchases are grouped below them.

Over the last 13 months insiders sold $24.7M in 18 sales and bought nothing on the open market; 92 other transactions (awards, exercises, tax withholding, gifts and plan purchases).

Date	Insider	Action	Shares	Price	Value	Held after	Filing
Sep 1, 2026Form 4	Davis J. E.CEO and President · DirectorSold · $2.4M · 10,000 sh · 10b5-1	Sold· 10b5-1 plan	10,000	$242.72	$2.4M	122,423	Form 4
Aug 28, 2026Form 4	PREVOZNIK MICHAEL ESVP & General CounselSold · $5.5M · 22,677 sh · 10b5-1	Sold· 10b5-1 plan	22,677	$242.88–$244.51	$5.5M	37,557	Form 4
Jul 28, 2026Form 4	DELANEY MARK ESVP & Chief Commercial OfficerSold · $376K · 1,600 sh · 10b5-1	Sold· 10b5-1 plan	1,600	$235.18	$376K	10,335	Form 4
Jun 4, 2026Form 4	KUPPUSAMY KARTHIKSVP, Clinical SolutionsSold · $1.6M · 8,147 sh · 10b5-1	Sold· 10b5-1 plan	8,147	$200.00	$1.6M	13,510	Form 4
Jun 1, 2026Form 4	Davis J. E.CEO and President · DirectorSold · $1.9M · 10,000 sh · 10b5-1	Sold· 10b5-1 plan	10,000	$194.14	$1.9M	132,423	Form 4
Mar 5, 2026Form 4	Doherty Catherine T.EVP, Regional BusinessesSold · $1.1M · 5,558 sh · 10b5-1	Sold· 10b5-1 plan	5,558	$206.21	$1.1M	67,122	Form 4
Mar 5, 2026Form 4	PREVOZNIK MICHAEL ESVP & General CounselSold · $800K · 3,878 sh · 10b5-1	Sold· 10b5-1 plan	3,878	$206.21	$800K	37,557	Form 4
Mar 5, 2026Form 4	Plewman PatrickSVP for Diagnostic ServicesSold · $589K · 2,855 sh · 10b5-1	Sold· 10b5-1 plan	2,855	$206.21	$589K	15,198	Form 4
Mar 4, 2026Form 4	KUPPUSAMY KARTHIKSVP, Clinical SolutionsSold · $538K · 2,628 sh	Sold	2,628	$204.86	$538K	13,441	Form 4
Mar 3, 2026Form 4	Doherty Catherine T.EVP, Regional BusinessesSold · $131K · 632 sh · 10b5-1	Sold· 10b5-1 plan	632	$207.73	$131K	67,122	Form 4
Mar 3, 2026Form 4	PREVOZNIK MICHAEL ESVP & General CounselSold · $109K · 526 sh · 10b5-1	Sold· 10b5-1 plan	526	$207.73	$109K	37,557	Form 4
Mar 3, 2026Form 4	Plewman PatrickSVP for Diagnostic ServicesSold · $85K · 410 sh · 10b5-1	Sold· 10b5-1 plan	410	$207.73	$85K	15,198	Form 4
Mar 2, 2026Form 4	Davis J. E.CEO and President · DirectorSold · $2.1M · 10,000 sh · 10b5-1	Sold· 10b5-1 plan	10,000	$212.52	$2.1M	117,185	Form 4
Feb 19, 2026Form 4	Doherty Catherine T.EVP, Regional BusinessesSold · $294K · 1,433 sh · 10b5-1	Sold· 10b5-1 plan	1,433	$204.83	$294K	68,402	Form 4
Feb 19, 2026Form 4	PREVOZNIK MICHAEL ESVP & General CounselSold · $228K · 1,111 sh · 10b5-1	Sold· 10b5-1 plan	1,111	$204.83	$228K	38,371	Form 4
Feb 19, 2026Form 4	Plewman PatrickSVP for Diagnostic ServicesSold · $196K · 958 sh · 10b5-1	Sold· 10b5-1 plan	958	$204.83	$196K	15,838	Form 4
Feb 13, 2026Form 4	Doherty Catherine T.EVP, Regional BusinessesSold · $5.4M · 26,165 sh · 10b5-1	Sold· 10b5-1 plan	26,165	$205.21–$209.10	$5.4M	68,068	Form 4
Feb 10, 2026Form 4	Plewman PatrickSVP for Diagnostic ServicesSold · $1.2M · 5,662 sh · 10b5-1	Sold· 10b5-1 plan	5,662	$204.00	$1.2M	15,381	Form 4

Awards, exercises, withholding and plan purchases · 92 transactions

Date	Insider	Action	Shares	Price	Value	Held after	Filing
Oct 1, 2026Form 4	WENTWORTH TIMOTHY CDirectorAward · Phantom Stock Units · $0 · 135 sh	Award· Phantom Stock Units	135	$0.00	$0	477	Form 4
Aug 28, 2026Form 4	PREVOZNIK MICHAEL ESVP & General CounselExercise or conversion · $2.5M · 22,677 sh · 10b5-1	Exercise or conversion· 10b5-1 plan	22,677	$112.17	$2.5M	60,234	Form 4
Aug 28, 2026Form 4	PREVOZNIK MICHAEL ESVP & General CounselExercise or conversion · Non-Qualifed Stock Option … · $2.5M · 22,677 sh · 10b5-1	Exercise or conversion· Non-Qualifed Stock Option …· 10b5-1 plan	22,677	$112.17	$2.5M	0	Form 4
Aug 28, 2026Form 4	PREVOZNIK MICHAEL ESVP & General CounselGift · $0 · 1,000 sh · 10b5-1	Gift· 10b5-1 plan	1,000	$0.00	$0	36,557	Form 4
Jul 22, 2026Form 4	SAMAD SAMExecutive Vice President & CFOAward · $21K · 102 sh	Award	102	$206.81	$21K	33,478	Form 4
Jul 22, 2026Form 4	Gregg Vicky BDirectorAward · $15K · 72 sh	Award	72	$206.81	$15K	18,386	Form 4
Jul 22, 2026Form 4	Plewman PatrickSVP for Diagnostic ServicesOther · $9,513 · 46 sh	Other	46	$206.81	$9,513	15,293	Form 4
Jul 22, 2026Form 4	KUPPUSAMY KARTHIKSVP, Clinical SolutionsOther · $7,652 · 37 sh	Other	37	$206.81	$7,652	13,557	Form 4
Jul 22, 2026Form 4	DELANEY MARK ESVP & Chief Commercial OfficerOther · $7,031 · 34 sh	Other	34	$206.81	$7,031	11,935	Form 4
Jul 22, 2026Form 4	MAIN TIMOTHY LDirectorOther · $4,343 · 21 sh	Other	21	$206.81	$4,343	22,460	Form 4
Jul 22, 2026Form 4	CARTER ROBERT BDirectorOther · $2,275 · 11 sh	Other	11	$206.80	$2,275	3,864	Form 4
Jul 22, 2026Form 4	Lassiter Wright IIIDirectorOther · $1,241 · 6 sh	Other	6	$206.81	$1,241	10,323	Form 4
Jul 1, 2026Form 4	WENTWORTH TIMOTHY CDirectorAward · Phantom Stock Units · $0 · 144 sh	Award· Phantom Stock Units	144	$0.00	$0	342	Form 4
Jun 4, 2026Form 4	KUPPUSAMY KARTHIKSVP, Clinical SolutionsExercise or conversion · $1.0M · 8,147 sh · 10b5-1	Exercise or conversion· 10b5-1 plan	8,147	$121.81–$127.73	$1.0M	21,657	Form 4
Jun 4, 2026Form 4	KUPPUSAMY KARTHIKSVP, Clinical SolutionsExercise or conversion · Non-Qualifed Stock Option … · $1.0M · 8,147 sh · 10b5-1	Exercise or conversion· Non-Qualifed Stock Option …· 10b5-1 plan	8,147	$121.81–$127.73	$1.0M	0	Form 4
May 20, 2026Form 4	PFEIFFER GARY MDirectorAward · $0 · 1,142 sh	Award	1,142	$0.00	$0	31,005	Form 4
May 20, 2026Form 4	MAIN TIMOTHY LDirectorAward · $0 · 1,142 sh	Award	1,142	$0.00	$0	27,439	Form 4
May 20, 2026Form 4	CARTER ROBERT BDirectorAward · $0 · 1,142 sh	Award	1,142	$0.00	$0	3,853	Form 4
May 20, 2026Form 4	RING TIMOTHY MDirectorAward · $0 · 1,142 sh	Award	1,142	$0.00	$0	31,140	Form 4
May 20, 2026Form 4	MORRISON DENISE MDirectorAward · $0 · 1,142 sh	Award	1,142	$0.00	$0	11,929	Form 4
May 20, 2026Form 4	WENTWORTH TIMOTHY CDirectorAward · $0 · 1,142 sh	Award	1,142	$0.00	$0	1,358	Form 4
May 20, 2026Form 4	Gregg Vicky BDirectorAward · $0 · 1,142 sh	Award	1,142	$0.00	$0	18,314	Form 4
May 20, 2026Form 4	Doi TraceyDirectorAward · $0 · 1,142 sh	Award	1,142	$0.00	$0	7,748	Form 4
May 20, 2026Form 4	Diaz LuisDirectorAward · $0 · 1,142 sh	Award	1,142	$0.00	$0	5,196	Form 4
May 20, 2026Form 4	Lassiter Wright IIIDirectorAward · $0 · 1,142 sh	Award	1,142	$0.00	$0	10,317	Form 4
Apr 20, 2026Form 4	SAMAD SAMExecutive Vice President & CFOAward · $21K · 108 sh	Award	108	$194.70	$21K	33,376	Form 4
Apr 20, 2026Form 4	Gregg Vicky BDirectorAward · $13K · 68 sh	Award	68	$194.70	$13K	17,172	Form 4
Apr 20, 2026Form 4	Plewman PatrickSVP for Diagnostic ServicesOther · $9,540 · 49 sh	Other	49	$194.70	$9,540	15,247	Form 4
Apr 20, 2026Form 4	KUPPUSAMY KARTHIKSVP, Clinical SolutionsOther · $7,593 · 39 sh	Other	39	$194.70	$7,593	13,490	Form 4
Apr 20, 2026Form 4	DELANEY MARK ESVP & Chief Commercial OfficerOther · $7,204 · 37 sh	Other	37	$194.70	$7,204	11,901	Form 4
Apr 20, 2026Form 4	CARTER ROBERT BDirectorOther · $1,363 · 7 sh	Other	7	$194.70	$1,363	2,711	Form 4
Apr 20, 2026Form 4	Lassiter Wright IIIDirectorOther · $1,168 · 6 sh	Other	6	$194.70	$1,168	9,063	Form 4
Apr 1, 2026Form 4	WENTWORTH TIMOTHY CDirectorAward · Phantom Stock Units · $0 · 198 sh	Award· Phantom Stock Units	198	$0.00	$0	198	Form 4
Mar 9, 2026Form 4	WENTWORTH TIMOTHY CDirectorAward · $0 · 215 sh	Award	215	$0.00	$0	215	Form 4
Mar 4, 2026Form 4	Davis J. E.CEO and President · DirectorAward · $10.6M · 51,652 sh	Award	51,652	$204.86	$10.6M	168,837	Form 4
Mar 4, 2026Form 4	Davis J. E.CEO and President · DirectorTax withholding · $5.4M · 26,414 sh	Tax withholding	26,414	$204.86	$5.4M	142,423	Form 4
Mar 4, 2026Form 4	SAMAD SAMExecutive Vice President & CFOAward · $2.9M · 13,947 sh	Award	13,947	$204.86	$2.9M	40,988	Form 4
Mar 4, 2026Form 4	Doherty Catherine T.EVP, Regional BusinessesAward · $2.3M · 11,364 sh · 10b5-1	Award· 10b5-1 plan	11,364	$204.86	$2.3M	78,486	Form 4
Mar 4, 2026Form 4	SAMAD SAMExecutive Vice President & CFOTax withholding · $1.6M · 7,720 sh	Tax withholding	7,720	$204.86	$1.6M	33,268	Form 4
Mar 4, 2026Form 4	PREVOZNIK MICHAEL ESVP & General CounselAward · $1.5M · 7,232 sh · 10b5-1	Award· 10b5-1 plan	7,232	$204.86	$1.5M	44,789	Form 4
Mar 4, 2026Form 4	KUPPUSAMY KARTHIKSVP, Clinical SolutionsAward · $1.3M · 6,200 sh	Award	6,200	$204.86	$1.3M	16,069	Form 4
Mar 4, 2026Form 4	Doherty Catherine T.EVP, Regional BusinessesTax withholding · $1.2M · 5,806 sh · 10b5-1	Tax withholding· 10b5-1 plan	5,806	$204.86	$1.2M	72,680	Form 4
Mar 4, 2026Form 4	Plewman PatrickSVP for Diagnostic ServicesAward · $1.2M · 5,682 sh · 10b5-1	Award· 10b5-1 plan	5,682	$204.86	$1.2M	20,880	Form 4
Mar 4, 2026Form 4	DELANEY MARK ESVP & Chief Commercial OfficerAward · $1.2M · 5,682 sh	Award	5,682	$204.86	$1.2M	14,190	Form 4
Mar 4, 2026Form 4	PREVOZNIK MICHAEL ESVP & General CounselTax withholding · $687K · 3,354 sh · 10b5-1	Tax withholding· 10b5-1 plan	3,354	$204.86	$687K	41,435	Form 4
Mar 4, 2026Form 4	Plewman PatrickSVP for Diagnostic ServicesTax withholding · $579K · 2,827 sh · 10b5-1	Tax withholding· 10b5-1 plan	2,827	$204.86	$579K	18,053	Form 4
Mar 4, 2026Form 4	DELANEY MARK ESVP & Chief Commercial OfficerTax withholding · $477K · 2,326 sh	Tax withholding	2,326	$204.86	$477K	11,864	Form 4
Mar 4, 2026Form 4	Deppe Michael JSVP, Corp. Controller & CAOAward · $302K · 1,473 sh	Award	1,473	$204.86	$302K	35,946	Form 4
Mar 4, 2026Form 4	Deppe Michael JSVP, Corp. Controller & CAOTax withholding · $154K · 750 sh	Tax withholding	750	$204.86	$154K	35,196	Form 4
Mar 2, 2026Form 4	Davis J. E.CEO and President · DirectorTax withholding · $608K · 2,968 sh · 10b5-1	Tax withholding· 10b5-1 plan	2,968	$204.86	$608K	127,185	Form 4
Mar 2, 2026Form 4	SAMAD SAMExecutive Vice President & CFOTax withholding · $178K · 869 sh	Tax withholding	869	$204.86	$178K	27,041	Form 4
Mar 2, 2026Form 4	Doherty Catherine T.EVP, Regional BusinessesTax withholding · $133K · 648 sh · 10b5-1	Tax withholding· 10b5-1 plan	648	$204.86	$133K	67,754	Form 4
Mar 2, 2026Form 4	PREVOZNIK MICHAEL ESVP & General CounselTax withholding · $59K · 288 sh · 10b5-1	Tax withholding· 10b5-1 plan	288	$204.86	$59K	38,083	Form 4
Mar 2, 2026Form 4	Plewman PatrickSVP for Diagnostic ServicesTax withholding · $47K · 230 sh · 10b5-1	Tax withholding· 10b5-1 plan	230	$204.86	$47K	15,608	Form 4
Mar 2, 2026Form 4	KUPPUSAMY KARTHIKSVP, Clinical SolutionsTax withholding · $42K · 205 sh	Tax withholding	205	$204.86	$42K	9,869	Form 4
Mar 2, 2026Form 4	DELANEY MARK ESVP & Chief Commercial OfficerTax withholding · $39K · 188 sh	Tax withholding	188	$204.86	$39K	8,508	Form 4
Mar 2, 2026Form 4	Deppe Michael JSVP, Corp. Controller & CAOTax withholding · $18K · 88 sh	Tax withholding	88	$204.86	$18K	34,473	Form 4
Feb 18, 2026Form 4	Davis J. E.CEO and President · DirectorTax withholding · $1.3M · 6,184 sh	Tax withholding	6,184	$206.99–$210.01	$1.3M	130,153	Form 4
Feb 18, 2026Form 4	SAMAD SAMExecutive Vice President & CFOTax withholding · $389K · 1,865 sh	Tax withholding	1,865	$206.99–$210.01	$389K	27,841	Form 4
Feb 18, 2026Form 4	Doherty Catherine T.EVP, Regional BusinessesTax withholding · $242K · 1,161 sh · 10b5-1	Tax withholding· 10b5-1 plan	1,161	$206.99–$210.01	$242K	69,835	Form 4
Feb 18, 2026Form 4	PREVOZNIK MICHAEL ESVP & General CounselTax withholding · $135K · 648 sh · 10b5-1	Tax withholding· 10b5-1 plan	648	$206.99–$210.01	$135K	39,482	Form 4
Feb 18, 2026Form 4	Plewman PatrickSVP for Diagnostic ServicesTax withholding · $112K · 537 sh · 10b5-1	Tax withholding· 10b5-1 plan	537	$206.99–$210.01	$112K	16,796	Form 4
Feb 18, 2026Form 4	KUPPUSAMY KARTHIKSVP, Clinical SolutionsTax withholding · $107K · 511 sh	Tax withholding	511	$206.99–$210.01	$107K	7,914	Form 4
Feb 18, 2026Form 4	DELANEY MARK ESVP & Chief Commercial OfficerTax withholding · $91K · 435 sh	Tax withholding	435	$206.99–$210.01	$91K	8,681	Form 4
Feb 18, 2026Form 4	Deppe Michael JSVP, Corp. Controller & CAOTax withholding · $38K · 182 sh	Tax withholding	182	$206.99–$210.01	$38K	34,560	Form 4
Feb 18, 2026Form 4	Davis J. E.CEO and President · DirectorAward · Non-Qualifed Stock Option … · $0 · 73,225 sh	Award· Non-Qualifed Stock Option …	73,225	$0.00	$0	73,225	Form 4
Feb 18, 2026Form 4	SAMAD SAMExecutive Vice President & CFOAward · Non-Qualifed Stock Option … · $0 · 18,303 sh	Award· Non-Qualifed Stock Option …	18,303	$0.00	$0	18,303	Form 4
Feb 18, 2026Form 4	Davis J. E.CEO and President · DirectorAward · $0 · 15,857 sh	Award	15,857	$0.00	$0	136,337	Form 4
Feb 18, 2026Form 4	Doherty Catherine T.EVP, Regional BusinessesAward · Non-Qualifed Stock Option … · $0 · 13,514 sh · 10b5-1	Award· Non-Qualifed Stock Option …· 10b5-1 plan	13,514	$0.00	$0	13,514	Form 4
Feb 18, 2026Form 4	KUPPUSAMY KARTHIKSVP, Clinical SolutionsAward · Non-Qualifed Stock Option … · $0 · 9,853 sh	Award· Non-Qualifed Stock Option …	9,853	$0.00	$0	9,853	Form 4
Feb 18, 2026Form 4	PREVOZNIK MICHAEL ESVP & General CounselAward · Non-Qualifed Stock Option … · $0 · 9,289 sh · 10b5-1	Award· Non-Qualifed Stock Option …· 10b5-1 plan	9,289	$0.00	$0	9,289	Form 4
Feb 18, 2026Form 4	Plewman PatrickSVP for Diagnostic ServicesAward · Non-Qualifed Stock Option … · $0 · 9,009 sh · 10b5-1	Award· Non-Qualifed Stock Option …· 10b5-1 plan	9,009	$0.00	$0	9,009	Form 4
Feb 18, 2026Form 4	DELANEY MARK ESVP & Chief Commercial OfficerAward · Non-Qualifed Stock Option … · $0 · 7,332 sh	Award· Non-Qualifed Stock Option …	7,332	$0.00	$0	7,332	Form 4
Feb 18, 2026Form 4	SAMAD SAMExecutive Vice President & CFOAward · $0 · 3,965 sh	Award	3,965	$0.00	$0	29,706	Form 4
Feb 18, 2026Form 4	Doherty Catherine T.EVP, Regional BusinessesAward · $0 · 2,928 sh · 10b5-1	Award· 10b5-1 plan	2,928	$0.00	$0	70,996	Form 4
Feb 18, 2026Form 4	KUPPUSAMY KARTHIKSVP, Clinical SolutionsAward · $0 · 2,135 sh	Award	2,135	$0.00	$0	10,049	Form 4
Feb 18, 2026Form 4	PREVOZNIK MICHAEL ESVP & General CounselAward · $0 · 2,013 sh · 10b5-1	Award· 10b5-1 plan	2,013	$0.00	$0	40,130	Form 4
Feb 18, 2026Form 4	Plewman PatrickSVP for Diagnostic ServicesAward · $0 · 1,952 sh · 10b5-1	Award· 10b5-1 plan	1,952	$0.00	$0	17,333	Form 4
Feb 18, 2026Form 4	Deppe Michael JSVP, Corp. Controller & CAOAward · Non-Qualifed Stock Option … · $0 · 1,688 sh	Award· Non-Qualifed Stock Option …	1,688	$0.00	$0	1,688	Form 4
Feb 18, 2026Form 4	DELANEY MARK ESVP & Chief Commercial OfficerAward · $0 · 1,586 sh	Award	1,586	$0.00	$0	9,116	Form 4
Feb 18, 2026Form 4	Deppe Michael JSVP, Corp. Controller & CAOAward · $0 · 366 sh	Award	366	$0.00	$0	34,742	Form 4
Feb 13, 2026Form 4	Doherty Catherine T.EVP, Regional BusinessesExercise or conversion · $2.9M · 26,165 sh · 10b5-1	Exercise or conversion· 10b5-1 plan	26,165	$112.17	$2.9M	94,233	Form 4
Feb 13, 2026Form 4	Doherty Catherine T.EVP, Regional BusinessesExercise or conversion · Non-Qualifed Stock Option … · $2.9M · 26,165 sh · 10b5-1	Exercise or conversion· Non-Qualifed Stock Option …· 10b5-1 plan	26,165	$112.17	$2.9M	0	Form 4
Feb 10, 2026Form 4	Plewman PatrickSVP for Diagnostic ServicesExercise or conversion · $690K · 5,662 sh · 10b5-1	Exercise or conversion· 10b5-1 plan	5,662	$121.81	$690K	21,043	Form 4
Feb 10, 2026Form 4	Plewman PatrickSVP for Diagnostic ServicesExercise or conversion · Non-Qualifed Stock Option … · $690K · 5,662 sh · 10b5-1	Exercise or conversion· Non-Qualifed Stock Option …· 10b5-1 plan	5,662	$121.81	$690K	0	Form 4
Jan 28, 2026Form 4	SAMAD SAMExecutive Vice President & CFOAward · $13K · 69 sh	Award	69	$183.51	$13K	27,910	Form 4
Jan 28, 2026Form 4	Gregg Vicky BDirectorOther · $12K · 67 sh	Other	67	$183.51	$12K	17,104	Form 4
Jan 28, 2026Form 4	Plewman PatrickSVP for Diagnostic ServicesAward · $8,809 · 48 sh · 10b5-1	Award· 10b5-1 plan	48	$183.51	$8,809	15,381	Form 4
Jan 28, 2026Form 4	KUPPUSAMY KARTHIKSVP, Clinical SolutionsOther · $2,936 · 16 sh	Other	16	$183.52	$2,936	10,065	Form 4
Jan 28, 2026Form 4	DELANEY MARK ESVP & Chief Commercial OfficerOther · $2,753 · 15 sh	Other	15	$183.51	$2,753	8,696	Form 4
Jan 28, 2026Form 4	Lassiter Wright IIIDirectorOther · $1,285 · 7 sh	Other	7	$183.51	$1,285	9,057	Form 4
Jan 28, 2026Form 4	CARTER ROBERT BDirectorOther · $1,101 · 6 sh	Other	6	$183.51	$1,101	2,704	Form 4

Reports and proxy statements#

Annual reports (10-K, 20-F, 40-F), quarterly reports (10-Q), current reports (8-K, 6-K) and proxy statements, newest first. An 8-K that furnishes a press release is headed by the release’s headline, its items beneath; any other 8-K is described by its items. A form opens the press release where there is one, else the document on EDGAR, or the filing’s index where it furnishes other exhibits.

2026 · 14 filings

Filed	Form	What it is	Period
Oct 6, 20268-K	8-K	Directors or officers; compensation	Oct 6, 2026
Jul 23, 202610-Q	10-Q	Quarterly report, Q2 2026 — revenue $3.04B (+10% y/y), net income $320.0M, EPS $2.84	Jun 30, 2026
Jul 23, 20268-K	8-K	Earnings release — EPS $3.12 vs $2.81 est. (+11.0%); revenue $3.04B (+10% y/y) 8.6%	Jul 23, 2026
May 21, 20268-K	8-K	Shareholder vote results	May 20, 2026
May 8, 20268-K	8-K	Material definitive agreement	May 6, 2026
May 1, 20268-K	8-K	Quest Diagnostics Prices $500 Million of Senior NotesOther events	Apr 27, 2026
Apr 22, 202610-Q	10-Q	Quarterly report, Q1 2026 — revenue $2.90B (+9% y/y), net income $252.0M, EPS $2.24	Mar 31, 2026
Apr 21, 20268-K	8-K	Earnings release — EPS $2.50 vs $2.37 est. (+5.5%); revenue $2.90B (+9% y/y) 4.4%	Apr 21, 2026
Apr 6, 2026DEFA14A	DEFA14A	Additional proxy materials	—
Apr 6, 2026DEF 14A	DEF 14A	Proxy statement	May 20, 2026
Mar 12, 20268-K	8-K	Quest Diagnostics Elects Timothy Wentworth, Former CEO of Walgreens Boots Alliance, Evernorth Health Services and Express Scripts, to Board of DirectorsDirectors or officers; compensation; Regulation FD disclosure	Mar 9, 2026
Feb 26, 202610-K	10-K	Annual report, FY2025 — revenue $11.04B (+12% y/y), net income $992.0M, EPS $8.75	Dec 31, 2025
Feb 10, 20268-K	8-K	Earnings release — EPS $2.42 vs $2.36 est. (+3.0%); revenue $2.81B (+7% y/y) 7.4%	Feb 10, 2026
Jan 12, 20268-K	8-K	Results of operations; Regulation FD disclosure	Jan 12, 2026

2025 · 14 filings

Filed	Form	What it is	Period
Oct 21, 20258-K	8-K	Earnings release — EPS $2.60 vs $2.51 est. (+3.6%); revenue $2.82B (+13% y/y) 3.0%	Oct 21, 2025
Oct 21, 202510-Q	10-Q	Quarterly report, Q3 2025 — revenue $2.82B (+13% y/y), net income $245.0M, EPS $2.16	Sep 30, 2025
Jul 23, 202510-Q	10-Q	Quarterly report, Q2 2025 — revenue $2.76B (+15% y/y), net income $282.0M, EPS $2.47	Jun 30, 2025
Jul 22, 20258-K	8-K	Earnings release — EPS $2.62 vs $2.57 est. (+1.9%); revenue $2.76B (+15% y/y) 7.1%	Jul 22, 2025
May 22, 20258-K	8-K	Shareholder vote results	May 15, 2025
Apr 23, 202510-Q	10-Q	Quarterly report, Q1 2025 — revenue $2.65B (+12% y/y), net income $220.0M, EPS $1.94	Mar 31, 2025
Apr 22, 20258-K	8-K	Earnings release — EPS $2.21 vs $2.15 est. (+2.8%); revenue $2.65B (+12% y/y) 6.8%	Apr 22, 2025
Apr 11, 2025DEFA14A	DEFA14A	Additional proxy materials	—
Apr 4, 2025DEFA14A	DEFA14A	Additional proxy materials	—
Apr 4, 2025DEF 14A	DEF 14A	Proxy statement	May 15, 2025
Mar 19, 20258-K	8-K	Regulation FD disclosure	Mar 19, 2025
Mar 19, 20258-K	8-K	Regulation FD disclosure	Mar 19, 2025
Feb 20, 202510-K	10-K	Annual report, FY2024 — revenue $9.87B (+7% y/y), net income $871.0M, EPS $7.69	Dec 31, 2024
Jan 30, 20258-K	8-K	Earnings release — EPS $2.23 vs $2.19 est. (+1.8%); revenue $2.62B (+15% y/y) 5.6%	Jan 30, 2025

2024 · 17 filings

Filed	Form	What it is	Period
Oct 23, 202410-Q	10-Q	Quarterly report, Q3 2024 — revenue $2.49B (+8% y/y), net income $226.0M, EPS $1.99	Sep 30, 2024
Oct 22, 20248-K	8-K	Earnings release — EPS $2.30 vs $2.26 est. (+1.8%); revenue $2.49B (+8% y/y) 6.9%	Oct 22, 2024
Aug 29, 20248-K	8-K	Other events	Aug 23, 2024
Aug 19, 20248-K	8-K	Material definitive agreement; Charter, bylaws or fiscal-year change; Other events	Aug 14, 2024
Jul 24, 202410-Q	10-Q	Quarterly report, Q2 2024 — revenue $2.40B (+3% y/y), net income $229.0M, EPS $2.03	Jun 30, 2024
Jul 23, 20248-K	8-K	Earnings release — EPS $2.35 vs $2.31 est. (+1.7%); revenue $2.40B (+3% y/y) 4.3%	Jul 23, 2024
Jul 3, 20248-K	8-K	Material definitive agreement; Regulation FD disclosure	Jul 2, 2024
May 21, 20248-K	8-K	Directors or officers; compensation; Regulation FD disclosure	May 16, 2024
May 21, 20248-K	8-K	Charter, bylaws or fiscal-year change; Shareholder vote results	May 16, 2024
Apr 24, 202410-Q	10-Q	Quarterly report, Q1 2024 — revenue $2.37B (+2% y/y), net income $194.0M, EPS $1.72	Mar 31, 2024
Apr 23, 20248-K	8-K	Earnings release — EPS $2.04 vs $1.86 est. (+9.7%); revenue $2.37B (+2% y/y) 5.1%	Apr 23, 2024
Apr 11, 2024PX14A6G	PX14A6G	Shareholder exempt solicitation	—
Apr 5, 2024DEFA14A	DEFA14A	Additional proxy materials	—
Apr 5, 2024DEF 14A	DEF 14A	Proxy statement	May 16, 2024
Mar 25, 2024PRE 14A	PRE 14A	Preliminary proxy statement	May 16, 2024
Feb 22, 202410-K	10-K	Annual report, FY2023 — revenue $9.25B (−6% y/y), net income $854.0M, EPS $7.49	Dec 31, 2023
Feb 1, 20248-K	8-K	Earnings release — EPS $2.15 vs $2.14 est. (+0.5%); revenue $2.29B (−2% y/y) 1.0%	Feb 1, 2024

2023 · 16 filings — 9 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms

Filed	Form	What it is	Period
Oct 25, 202310-Q	10-Q	Quarterly report, Q3 2023 — revenue $2.29B (−8% y/y), net income $225.0M, EPS $1.96	Sep 30, 2023
Jul 27, 202310-Q	10-Q	Quarterly report, Q2 2023 — revenue $2.34B (−5% y/y), net income $235.0M, EPS $2.05	Jun 30, 2023
Apr 28, 202310-Q	10-Q	Quarterly report, Q1 2023 — revenue $2.33B (−11% y/y), net income $202.0M, EPS $1.78	Mar 31, 2023
Apr 10, 2023PX14A6G	PX14A6G	Shareholder exempt solicitation	—
Apr 6, 2023DEFA14A	DEFA14A	Additional proxy materials	—
Apr 6, 2023DEF 14A	DEF 14A	Proxy statement	—
Feb 21, 202310-K	10-K	Annual report, FY2022 — revenue $9.88B (−8% y/y), net income $946.0M, EPS $7.97	Dec 31, 2022

9 current reports (8-K) not listed; the year is on EDGAR.

2022 · 24 filings — 15 × 8-K, 3 × 10-Q, 2 × 8-K/A and 4 other forms

Filed	Form	What it is	Period
Oct 21, 202210-Q	10-Q	Quarterly report, Q3 2022 — revenue $2.49B (−10% y/y), net income $256.0M, EPS $2.17	Sep 30, 2022
Jul 22, 202210-Q	10-Q	Quarterly report, Q2 2022 — revenue $2.45B (−4% y/y), net income $234.0M, EPS $1.96	Jun 30, 2022
Apr 22, 202210-Q	10-Q	Quarterly report, Q1 2022 — revenue $2.61B (−4% y/y), net income $355.0M, EPS $2.92	Mar 31, 2022
Apr 22, 2022PX14A6G	PX14A6G	Shareholder exempt solicitation	—
Apr 19, 2022DEF 14A	DEF 14A	Proxy statement	May 18, 2022
Apr 5, 2022PRE 14A	PRE 14A	Preliminary proxy statement	May 18, 2022
Feb 28, 202210-K	10-K	Annual report, FY2021 — revenue $10.79B (+14% y/y), net income $2.00B, EPS $15.55	Dec 31, 2021

17 current reports (8-K) not listed; the year is on EDGAR.

2021 · 20 filings — 13 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms

Filed	Form	What it is	Period
Oct 22, 202110-Q	10-Q	Quarterly report, Q3 2021 — revenue $2.77B (−0% y/y), net income $505.0M, EPS $4.02	Sep 30, 2021
Jul 23, 202110-Q	10-Q	Quarterly report, Q2 2021 — revenue $2.55B (+40% y/y), net income $631.0M, EPS $4.96	Jun 30, 2021
Apr 23, 202110-Q	10-Q	Quarterly report, Q1 2021 — revenue $2.72B (+49% y/y), net income $469.0M, EPS $3.46	Mar 31, 2021
Apr 9, 2021DEFA14A	DEFA14A	Additional proxy materials	—
Apr 9, 2021DEF 14A	DEF 14A	Proxy statement	May 21, 2021
Feb 22, 202110-K	10-K	Annual report, FY2020 — revenue $9.44B (+22% y/y), net income $1.43B, EPS $10.47	Dec 31, 2020

14 current reports (8-K) not listed; the year is on EDGAR.

2020 · 24 filings — 17 × 8-K, 3 × 10-Q, 2 × DEFA14A and 2 other forms

Filed	Form	What it is	Period
Oct 23, 202010-Q	10-Q	Quarterly report, Q3 2020 — revenue $2.79B (+42% y/y), net income $568.0M, EPS $4.14	Sep 30, 2020
Jul 24, 202010-Q	10-Q	Quarterly report, Q2 2020 — revenue $1.83B (−6% y/y), net income $185.0M, EPS $1.36	Jun 30, 2020
May 5, 2020DEFA14A	DEFA14A	Additional proxy materials	—
May 4, 202010-Q	10-Q	Quarterly report, Q1 2020 — revenue $1.82B (−4% y/y), net income $99.0M, EPS $0.73	Mar 31, 2020
Apr 8, 2020DEFA14A	DEFA14A	Additional proxy materials	—
Apr 8, 2020DEF 14A	DEF 14A	Proxy statement	May 19, 2020
Feb 20, 202010-K	10-K	Annual report, FY2019 — revenue $7.73B (+3% y/y), net income $858.0M, EPS $6.28	Dec 31, 2019

17 current reports (8-K) not listed; the year is on EDGAR.

2019 · 22 filings — 14 × 8-K, 3 × 10-Q, 2 × DEFA14A and 3 other forms

Filed	Form	What it is	Period
Oct 23, 201910-Q	10-Q	Quarterly report, Q3 2019 — revenue $1.96B (+4% y/y), net income $215.0M, EPS $1.56	Sep 30, 2019
Jul 24, 201910-Q	10-Q	Quarterly report, Q2 2019 — revenue $1.95B (+2% y/y), net income $226.0M, EPS $1.66	Jun 30, 2019
May 1, 2019DEFA14A	DEFA14A	Additional proxy materials	—
Apr 24, 201910-Q	10-Q	Quarterly report, Q1 2019 — revenue $1.89B (+0% y/y), net income $164.0M, EPS $1.20	Mar 31, 2019
Apr 3, 2019DEFA14A	DEFA14A	Additional proxy materials	—
Apr 3, 2019DEF 14A	DEF 14A	Proxy statement	May 14, 2019
Feb 21, 201910-K	10-K	Annual report, FY2018 — revenue $7.53B (+2% y/y), net income $736.0M, EPS $5.29	Dec 31, 2018

15 current reports (8-K) not listed; the year is on EDGAR.

2018 · 16 filings — 9 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms

Filed	Form	What it is	Period
Oct 24, 201810-Q	10-Q	Quarterly report, Q3 2018 — revenue $1.89B (+2% y/y), net income $213.0M, EPS $1.53	Sep 30, 2018
Jul 25, 201810-Q	10-Q	Quarterly report, Q2 2018 — revenue $1.92B (+3% y/y), net income $219.0M, EPS $1.57	Jun 30, 2018
Apr 20, 201810-Q	10-Q	Quarterly report, Q1 2018 — revenue $1.88B (+4% y/y), net income $177.0M, EPS $1.27	Mar 31, 2018
Apr 4, 2018DEFA14A	DEFA14A	Additional proxy materials	—
Apr 4, 2018DEF 14A	DEF 14A	Proxy statement	May 15, 2018
Mar 23, 2018PRE 14A	PRE 14A	Preliminary proxy statement	May 15, 2018
Feb 23, 201810-K	10-K	Annual report, FY2017 — revenue $7.40B (+3% y/y), net income $772.0M, EPS $5.50	Dec 31, 2017

9 current reports (8-K) not listed; the year is on EDGAR.

2017 · 17 filings — 10 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms

Filed	Form	What it is	Period
Oct 19, 201710-Q	10-Q	Quarterly report, Q3 2017 — revenue $1.86B (−2% y/y), net income $161.0M, EPS $1.15	Sep 30, 2017
Jul 25, 201710-Q	10-Q	Quarterly report, Q2 2017 — revenue $1.86B (−2% y/y), net income $193.0M, EPS $1.37	Jun 30, 2017
Apr 21, 201710-Q	10-Q	Quarterly report, Q1 2017 — revenue $1.82B (−2% y/y), net income $164.0M, EPS $1.16	Mar 31, 2017
Apr 6, 2017DEFA14A	DEFA14A	Additional proxy materials	—
Apr 5, 2017DEF 14A	DEF 14A	Proxy statement	May 16, 2017
Feb 22, 201710-K	10-K	Annual report, FY2016 — revenue $7.21B (−4% y/y), net income $645.0M, EPS $4.51	Dec 31, 2016

11 current reports (8-K) not listed; the year is on EDGAR.

2016 · 20 filings — 13 × 8-K, 3 × 10-Q, 2 × DEFA14A and 2 other forms

Counted, not listed; the year is on EDGAR.

2015 · 17 filings — 10 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms

Counted, not listed; the year is on EDGAR.

2014 · 20 filings — 12 × 8-K, 3 × 10-Q, 1 × 10-K and 4 other forms

Counted, not listed; the year is on EDGAR.

2013 · 27 filings — 19 × 8-K, 3 × 10-Q, 1 × 10-K and 4 other forms

Counted, not listed; the year is on EDGAR.

2012 · 20 filings — 12 × 8-K, 3 × 10-Q, 1 × 10-K and 4 other forms

Counted, not listed; the year is on EDGAR.

2011 · 23 filings — 15 × 8-K, 3 × 10-Q, 1 × 10-K and 4 other forms

Counted, not listed; the year is on EDGAR.

2010 · 13 filings — 7 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms

Counted, not listed; the year is on EDGAR.

2009 · 15 filings — 9 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms

Counted, not listed; the year is on EDGAR.

2008 · 15 filings — 9 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms

Counted, not listed; the year is on EDGAR.

2007 · 20 filings — 14 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms

Counted, not listed; the year is on EDGAR.

2006 · 20 filings — 13 × 8-K, 3 × 10-Q, 2 × 8-K/A and 2 other forms

Counted, not listed; the year is on EDGAR.

2005 · 19 filings — 11 × 8-K, 3 × 10-Q, 2 × DEFA14A and 3 other forms

Counted, not listed; the year is on EDGAR.

2004 · 15 filings — 10 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form

Counted, not listed; the year is on EDGAR.

2003 · 16 filings — 8 × 8-K, 3 × 10-Q, 2 × 8-K/A and 3 other forms

Counted, not listed; the year is on EDGAR.

2002 · 11 filings — 5 × 8-K, 3 × 10-Q, 1 × 10-K405 and 2 other forms

Counted, not listed; the year is on EDGAR.

2001 · 12 filings — 6 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms

Counted, not listed; the year is on EDGAR.

2000 · 7 filings — 3 × 10-Q, 1 × 10-K405, 1 × 8-K and 2 other forms

Counted, not listed; the year is on EDGAR.

1999 · 11 filings — 4 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms

Counted, not listed; the year is on EDGAR.

1998 · 6 filings — 3 × 10-Q, 1 × 10-K, 1 × 8-K and 1 other form

Counted, not listed; the year is on EDGAR.

1997 · 6 filings — 3 × 10-Q, 1 × 10-K, 1 × 10-K/A and 1 other form

Counted, not listed; the year is on EDGAR.

Insider, ownership and other filings#

Insider ownership (Forms 3, 4, 5 and 144), beneficial ownership (Schedules 13D and 13G), registration and prospectus (S-1, S-3, S-8, 424B and related) and the rest, counted by year, with the newest 25 of each of the latest 3 years shown. A Form 4 is one insider’s transaction report; a 13G is a passive holder above five percent.

2026 · 89 filings — 63 × 4, 17 × 144, 2 × 424B2 and 5 other forms

Filed	Form	What it is	Period
Oct 2, 20264	4	Insider transaction (Form 4)	Oct 1, 2026
Sep 3, 20264	4	Insider transaction (Form 4)	Sep 1, 2026
Sep 1, 2026144	144	Notice of proposed sale (Form 144)	—
Aug 31, 20264	4	Insider transaction (Form 4)	Aug 28, 2026
Aug 28, 2026144	144	Notice of proposed sale (Form 144)	—
Aug 14, 2026SCHEDULE 13G/A	SCHEDULE 13G/A	Other filings	—
Jul 29, 20264	4	Insider transaction (Form 4)	Jul 28, 2026
Jul 28, 2026144	144	Notice of proposed sale (Form 144)	—
Jul 27, 20264	4	Insider transaction (Form 4)	Jul 22, 2026
Jul 27, 20264	4	Insider transaction (Form 4)	Jul 22, 2026
Jul 27, 20264	4	Insider transaction (Form 4)	Jul 22, 2026
Jul 27, 20264	4	Insider transaction (Form 4)	Jul 22, 2026
Jul 27, 20264	4	Insider transaction (Form 4)	Jul 22, 2026
Jul 27, 20264	4	Insider transaction (Form 4)	Jul 22, 2026
Jul 27, 20264	4	Insider transaction (Form 4)	Jul 22, 2026
Jul 27, 20264	4	Insider transaction (Form 4)	Jul 22, 2026
Jul 2, 20264	4	Insider transaction (Form 4)	Jul 1, 2026
Jun 18, 202611-K	11-K	Employee plan annual report	Dec 31, 2025
Jun 8, 20264	4	Insider transaction (Form 4)	Jun 4, 2026
Jun 4, 2026144	144	Notice of proposed sale (Form 144)	—
Jun 2, 20264	4	Insider transaction (Form 4)	Jun 1, 2026
Jun 1, 2026144	144	Notice of proposed sale (Form 144)	—
May 21, 20264	4	Insider transaction (Form 4)	May 20, 2026
May 21, 20264	4	Insider transaction (Form 4)	May 20, 2026
May 21, 20264	4	Insider transaction (Form 4)	May 20, 2026

The newest 25 of 89 shown; the full year is on EDGAR.

2025 · 129 filings — 95 × 4, 29 × 144, 2 × SCHEDULE 13G/A and 3 other forms

Filed	Form	What it is	Period
Nov 28, 20254	4	Insider transaction (Form 4)	Nov 25, 2025
Nov 28, 20254	4	Insider transaction (Form 4)	Nov 25, 2025
Nov 25, 2025144	144	Notice of proposed sale (Form 144)	—
Nov 25, 2025144	144	Notice of proposed sale (Form 144)	—
Nov 20, 20254	4	Insider transaction (Form 4)	Nov 18, 2025
Nov 18, 2025144	144	Notice of proposed sale (Form 144)	—
Nov 7, 20254	4	Insider transaction (Form 4)	Nov 5, 2025
Oct 24, 20254	4	Insider transaction (Form 4)	Oct 21, 2025
Oct 24, 20254	4	Insider transaction (Form 4)	Oct 21, 2025
Oct 24, 20254	4	Insider transaction (Form 4)	Oct 21, 2025
Oct 24, 20254	4	Insider transaction (Form 4)	Oct 22, 2025
Oct 24, 20254	4	Insider transaction (Form 4)	Oct 21, 2025
Oct 24, 20254	4	Insider transaction (Form 4)	Oct 21, 2025
Oct 24, 20254	4	Insider transaction (Form 4)	Oct 21, 2025
Oct 22, 2025144	144	Notice of proposed sale (Form 144)	—
Oct 3, 20254	4	Insider transaction (Form 4)	Oct 1, 2025
Oct 3, 20254	4	Insider transaction (Form 4)	Oct 1, 2025
Sep 30, 20254	4	Insider transaction (Form 4)	Sep 26, 2025
Sep 26, 2025144	144	Notice of proposed sale (Form 144)	—
Sep 25, 20254	4	Insider transaction (Form 4)	Sep 23, 2025
Sep 24, 2025144	144	Notice of proposed sale (Form 144)	—
Sep 23, 2025144	144	Notice of proposed sale (Form 144)	—
Aug 25, 20254	4	Insider transaction (Form 4)	Aug 21, 2025
Aug 21, 20254	4	Insider transaction (Form 4)	Aug 19, 2025
Aug 21, 2025144	144	Notice of proposed sale (Form 144)	—

The newest 25 of 129 shown; the full year is on EDGAR.

2024 · 97 filings — 74 × 4, 14 × 144, 3 × SC 13G/A and 5 other forms

Filed	Form	What it is	Period
Dec 2, 20244	4	Insider transaction (Form 4)	Nov 29, 2024
Dec 2, 20244	4	Insider transaction (Form 4)	Nov 27, 2024
Nov 29, 2024144	144	Notice of proposed sale (Form 144)	—
Nov 27, 2024144	144	Notice of proposed sale (Form 144)	—
Nov 7, 20244	4	Insider transaction (Form 4)	Nov 6, 2024
Oct 30, 20244	4	Insider transaction (Form 4)	Oct 28, 2024
Oct 28, 2024144	144	Notice of proposed sale (Form 144)	—
Oct 25, 20244	4	Insider transaction (Form 4)	Oct 21, 2024
Oct 25, 20244	4	Insider transaction (Form 4)	Oct 21, 2024
Oct 25, 20244	4	Insider transaction (Form 4)	Oct 21, 2024
Oct 25, 20244	4	Insider transaction (Form 4)	Oct 21, 2024
Oct 25, 20244	4	Insider transaction (Form 4)	Oct 21, 2024
Oct 3, 20244	4	Insider transaction (Form 4)	Oct 1, 2024
Sep 26, 20244	4	Insider transaction (Form 4)	Sep 24, 2024
Sep 3, 20244	4	Insider transaction (Form 4)	Aug 29, 2024
Aug 29, 20244	4	Insider transaction (Form 4)	Aug 28, 2024
Aug 29, 2024144	144	Notice of proposed sale (Form 144)	—
Aug 28, 2024144	144	Notice of proposed sale (Form 144)	—
Aug 16, 20244	4	Insider transaction (Form 4)	Aug 14, 2024
Aug 16, 2024424B2	424B2	Prospectus supplement	—
Aug 15, 2024FWP	FWP	Free writing prospectus	—
Aug 15, 2024424B2	424B2	Prospectus supplement	—
Jul 26, 20244	4	Insider transaction (Form 4)	Jul 24, 2024
Jul 26, 20244	4	Insider transaction (Form 4)	Jul 22, 2024
Jul 26, 20244	4	Insider transaction (Form 4)	Jul 22, 2024

The newest 25 of 97 shown; the full year is on EDGAR.

2023 · 66 filings — 56 × 4, 3 × SC 13G/A, 2 × 424B2 and 5 other forms

Counted, not listed; the year is on EDGAR.

2022 · 58 filings — 47 × 4, 5 × 3, 3 × SC 13G/A and 3 other forms

Counted, not listed; the year is on EDGAR.

2021 · 48 filings — 44 × 4, 2 × SC 13G/A, 1 × 11-K and 1 other form

Counted, not listed; the year is on EDGAR.

2020 · 70 filings — 62 × 4, 3 × SC 13G/A, 2 × 424B2 and 3 other forms

Counted, not listed; the year is on EDGAR.

2019 · 82 filings — 66 × 4, 4 × 424B2, 3 × 3 and 6 other forms

Counted, not listed; the year is on EDGAR.

2018 · 71 filings — 64 × 4, 3 × SC 13G/A, 2 × 4/A and 2 other forms

Counted, not listed; the year is on EDGAR.

2017 · 81 filings — 72 × 4, 4 × SC 13G/A, 1 × 11-K and 4 other forms

Counted, not listed; the year is on EDGAR.

2016 · 74 filings — 58 × 4, 3 × SC 13G/A, 2 × 11-K and 10 other forms

Counted, not listed; the year is on EDGAR.

2015 · 69 filings — 49 × 4, 7 × S-8 POS, 3 × SC 13G/A and 9 other forms

Counted, not listed; the year is on EDGAR.

2014 · 73 filings — 56 × 4, 5 × SC 13G/A, 4 × 3 and 7 other forms

Counted, not listed; the year is on EDGAR.

2013 · 81 filings — 68 × 4, 3 × 3, 3 × SC 13G/A and 5 other forms

Counted, not listed; the year is on EDGAR.

2012 · 97 filings — 81 × 4, 4 × SC 13G, 3 × UPLOAD and 6 other forms

Counted, not listed; the year is on EDGAR.

2011 · 131 filings — 88 × 4, 13 × SC TO-T/A, 6 × UPLOAD and 13 other forms

Counted, not listed; the year is on EDGAR.

2010 · 52 filings — 40 × 4, 3 × UPLOAD, 2 × 11-K and 5 other forms

Counted, not listed; the year is on EDGAR.

2009 · 58 filings — 48 × 4, 3 × S-8, 2 × 11-K and 5 other forms

Counted, not listed; the year is on EDGAR.

2008 · 32 filings — 23 × 4, 7 × 4/A, 1 × 11-K and 1 other form

Counted, not listed; the year is on EDGAR.

2007 · 42 filings — 29 × 4, 2 × 3, 2 × UPLOAD and 9 other forms

Counted, not listed; the year is on EDGAR.

2006 · 50 filings — 39 × 4, 2 × S-8, 2 × UPLOAD and 7 other forms

Counted, not listed; the year is on EDGAR.

2005 · 51 filings — 43 × 4, 3 × 3, 1 × 11-K and 4 other forms

Counted, not listed; the year is on EDGAR.

2004 · 102 filings — 99 × 4, 2 × 3, 1 × 11-K

Counted, not listed; the year is on EDGAR.

2003 · 53 filings — 25 × 4, 9 × SC TO-T/A, 8 × 425 and 10 other forms

Counted, not listed; the year is on EDGAR.

2002 · 52 filings — 24 × 425, 19 × SC TO-T/A, 3 × S-4/A and 6 other forms

Counted, not listed; the year is on EDGAR.

2001 · 24 filings — 6 × S-3/A, 3 × S-3, 3 × SC 13D/A and 6 other forms

Counted, not listed; the year is on EDGAR.

2000 · 8 filings — 6 × SC 13G/A, 1 × SC 13D, 1 × SC 13D/A

Counted, not listed; the year is on EDGAR.

1999 · 12 filings — 7 × SC 13G/A, 2 × S-8, 2 × SC 13G and 1 other form

Counted, not listed; the year is on EDGAR.

1998 · 6 filings — 3 × SC 13G, 2 × S-8, 1 × SC 13G/A

Counted, not listed; the year is on EDGAR.

1997 · 1 filing — 1 × SC 13G

Counted, not listed; the year is on EDGAR.

1996 · 14 filings — 4 × 10-12B/A, 3 × S-1/A, 3 × S-8 and 4 other forms

Counted, not listed; the year is on EDGAR.

About this data#

Quest Diagnostics Incorporated (DGX) has 2,370 filings on EDGAR going back to 1996: 32 annual reports, 89 quarterly reports and 305 current reports, plus proxy statements, insider forms and ownership schedules. Its latest annual report, a 10-K, was filed on Feb 26, 2026 for the fiscal year ended Dec 31, 2025. The most recent 8-K, on Oct 6, 2026, covered directors or officers; compensation. Over the last 13 months insiders sold $24.7M in 18 sales and bought nothing on the open market; 92 other transactions (awards, exercises, tax withholding, gifts and plan purchases). Not investment advice.

Every row is a filing EDGAR lists for the registrants that have been Quest Diagnostics Incorporated, read from the SEC’s submissions index each morning; a filing accepted after that read appears the next day. Where a company changed its filing entity (a holding-company reorganisation, Google into Alphabet) the predecessor’s filings are shown for the years it filed as the company, derived from the filings themselves. Dates are the filing date; the period is the report’s own. The latest 3 years of reports are listed in full, the next years to 10 without their 8-Ks, and older years are counted; the other forms are counted too, with the newest 25 of each of the latest 3 years shown. Insider transactions are the Form 4 and Form 5 documents themselves, filed since January 2026, every number as the insider filed it: a day’s lots are summed, a blank price adds its shares and no dollars, and a purchase through an employee stock plan is a plan purchase, not insider buying. An 8-K’s headline is the first line of the press release it furnishes (Exhibit 99), read from the filing and shown word for word; where two independent readings of the exhibit do not agree, the 8-K is described by its items instead. The documents stay on sec.gov, public domain, and every link opens the SEC’s copy. ChartRow does not summarise or interpret filings.

FAQ#

Where can I read DGX's latest 10-K?: DGX's latest annual report, a 10-K, was filed on Feb 26, 2026 for the fiscal year ended Dec 31, 2025. It is linked above and opens on EDGAR, the SEC's own site, where every exhibit is also listed.
When did DGX last file an 8-K?: On Oct 6, 2026 it covered directors or officers; compensation. An 8-K reports a material event between quarterly reports; the one that furnishes the quarter's results is filed under Item 2.02, last on Jul 23, 2026.
Are DGX insiders buying or selling?: Over the last 13 months insiders sold $24.7M in 18 sales and bought nothing on the open market; 92 other transactions (awards, exercises, tax withholding, gifts and plan purchases). The most recent sale: Davis J. E. (CEO and President · Director) sold 10,000 shares on Sep 1, 2026 for $2.4M, under a 10b5-1 plan. Every figure is as the insider filed it on Form 4; a sale under a 10b5-1 plan was scheduled in advance.
How many SEC filings has DGX made?: 2,370 filings are on EDGAR under the registrant records that have been Quest Diagnostics Incorporated, going back to 1996; 1,504 of them are insider ownership forms (Forms 3, 4, 5 and 144).

DGX SEC filings (2026)

What happened, last 12 months#

October 2026

September 2026

August 2026

July 2026

June 2026

May 2026

April 2026

March 2026

February 2026

January 2026

October 2025

Insider transactions#

Reports and proxy statements#

Insider, ownership and other filings#

About this data#

FAQ#